Patents by Inventor Vanitha Ramakrishnan

Vanitha Ramakrishnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against cancer antigen TMEFF2 and uses thereof
    Publication number: 20040096392
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: March 7, 2003
    Publication date: May 20, 2004
    Applicant: Eos Biotechnology, Inc.
    Inventors: Vinay Bhaskar, Agustin de la Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
    Publication number: 20030228307
    Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.
    Type: Application
    Filed: May 16, 2003
    Publication date: December 11, 2003
    Applicants: COR Therapeutics Inc., Millennium Pharmaceuticals Inc.
    Inventors: Vanitha Ramakrishnan, Maria Amelia Escobedo, Larry J. Fretto
  • P2Y12 receptor
    Publication number: 20030170777
    Abstract: The present invention includes a novel subtype of the P2-purinergic receptor, referred to as the P2Y12 receptor. This receptor is expressed selectively in the platelets and brain, and couples to a pertussis toxin-sensitive G protein (Gi). Nucleic acids encoding the receptor and associated screening and therapeutic methods are also disclosed.
    Type: Application
    Filed: December 26, 2000
    Publication date: September 11, 2003
    Inventors: Pamela B. Conley, Hans-Michael Jantzen, Vanitha Ramakrishnan-DuBridge, David Jay Julius, Gunther Hollopeter
  • Transgenic animals having a modified glycoprotein V gene
    Publication number: 20030167487
    Abstract: The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of GP V, including the screening and identification of potential therapeutic agents.
    Type: Application
    Filed: February 5, 2001
    Publication date: September 4, 2003
    Inventors: Vanitha Ramakrishnan, David R. Phillips
  • INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR
    Publication number: 20030059425
    Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta-receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.
    Type: Application
    Filed: January 7, 1998
    Publication date: March 27, 2003
    Inventors: VANITHA RAMAKRISHNAN, MARIA AMELIA ESCOBEDO, LARRY J. FRETTO
  • Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
    Patent number: 5817310
    Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: October 6, 1998
    Assignee: COR Therapeutics, Inc.
    Inventors: Vanitha Ramakrishnan, Maria Amelia Escobedo, Larry J. Fretto, Nathalie Lokker